diabetes-777001_960_720

Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

pharmafile | February 15, 2019 | News story | Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes 

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself non-inferior to glimepiride in its ability to prolong the amount of time before the first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke in type 2 diabetes patients.

The CAROLINA trial – the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor – examined the efficacy of Trajenta in 6,033 patients with type 2 diabetes in addition to established CV disease or increased CV risk, compared to glimepiride sulphonylurea and standard of care. It provided the longest evaluation ever of a DPP-4 inhibitor in cardiovascular disease, with a median follow-up of over six years.

“Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit,” commented Dr Waheed Jamal, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine at Boehringer Ingelheim. “When other therapies such as DPP-4 inhibitors are considered for people with type 2 diabetes, physicians need a treatment with an established long-term safety profile. With these results, CAROLINA expands our understanding of the long-term cardiovascular safety of linagliptin, which now has one of the most comprehensive datasets on the cardiovascular safety of a DPP-4 inhibitor.”

Dr Jeff Emmick, Vice President, Product Development at Lilly Diabetes, added: “These data provide further confidence in the well-established safety and tolerability profile of linagliptin for the treatment of adults with type 2 diabetes. Linagliptin is an important option for physicians considering a DPP-4 inhibitor for their patients with type 2 diabetes. Boehringer Ingelheim and Lilly look forward to sharing the full results later this year.”

Matt Fellows

Related Content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …

Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets

Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) …

Latest content